Ashkan Emadi, MD, PhD, is a hematologist/medical oncologist, organic chemist, and professor of medicine and pharmacology at the University of Maryland School of Medicine, Marlene & Stewart Greenebaum Comprehensive Cancer Center (UMGCCC).
He has been working on changing the outcomes for acute leukemias in adults by designing, conducting, and analyzing rationally-based innovative strategies that will positively affect cures and translate into prolongation of meaningful survival. His in-depth knowledge and experience in organic chemistry and drug design, pre-clinical and clinical development, and drug approval covers the entire spectrum of drug development.
Dr. Emadi developed novel methodologies for the regiospecific synthesis of multiple naphthoquinone derivatives related to the natural product conocurvone, which exhibit HIV integrase inhibitory activity as well as anti-neoplastic activity. His clinical translational research is focused on exploiting and targeting glutamine and glucose metabolic pathways in neoplastic cells. He is the principal investigator of fully funded investigator-initiated clinical trials for the treatment of patients with newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) involving tryptophan and glutamine metabolisms.
Dr. Emadi is a recipient of the Martin and Mary Kilpatrick Award for exceptional ability and promise in chemistry and outstanding achievement in chemical research.
Mohamed Hersi, PharmD, BCPS, joined the clinical pharmacy staff at Memorial Hermann Memorial City Medical Center in 2013. His areas of interest include internal medicine and oncology.
Dr. Hersi received his PharmD from Texas Southern University College of Pharmacy & Health Sciences, and completed his PGY1 pharmacy practice residency at Michael E. DeBakey VA Medical Center.
Elias Jabbour, MD, is actively involved in research in acute and chronic forms of leukemia; and was actively involved in clinical trials that led to the approval of several drugs in chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), and acute lymphoblastic leukemia (ALL). He has assisted in the development of chemotherapeutic and biologic agents in leukemias, and has been involved in addressing the question of genomic instabilities in patients with low-risk MDS who may need earlier therapeutic intervention. This served as a rationale for the first study in the world randomizing such patients to either 5-azacitidine or decitabine. Dr. Jabbour has participated in numerous scientific meetings, authored or co-authored more than 400 peer-reviewed publications and abstracts, and serves as a reviewer for many scientific journals.
Dr. Jabbour is a recipient of several prestigious awards, among them merit awards from the American Society of Clinical Oncology and the American Society of Hematology. He also received several honors, including the Kimberly Patterson and Shannon Timmins fellowships, the 2007 Celgene Future Leader in Hematology Award, and the 2016 Young Investigator in Hematology Award.
Jeffrey Kendall, PsyD, has directed oncology supportive care departments within NCI-designated comprehensive cancer centers, academic medical centers, and community cancer centers for the past 20 years. He joined the University of Minnesota Cancer Care program in 2016 where he is dedicated to addressing the impact of cancer on individuals and families. Currently, his professional time is divided among direct patient care, program administration, program development, and research collaboration.
To raise awareness of the needs of cancer patients, he speaks nationally and internationally, and has published 38 journal articles and abstracts on topics related to psychosocial oncology and cancer survivorship. As a nationally recognized thought leader in his field, Dr. Kendall serves on committees for the American Psychosocial Oncology Society, the Association of Community Cancer Centers, the American Cancer Society as well as on the board of Suite Hope and A Breath of Hope Lung Foundation.
Dr. Kendall earned his degree from Indiana State University and completed his post-doctoral fellowship in psychosocial oncology at Roswell Park Cancer Institute in Buffalo, New York.
Sandra E. Kurtin, PhD, ANP-C, AOCN, is a PhD candidate, actively conducting her dissertation research on the use of mobile health applications aimed at improving health self-management among older adult cancer survivors and their caregivers. She is currently employed as a hematology/oncology nurse practitioner at the University of Arizona Cancer Center, and serves as an assistant professor of clinical medicine and adjunct clinical assistant professor of nursing at the University of Arizona.
Sandra is a member of the Advanced Practitioner Society for Hematology and Oncology (APSHO), American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), American Academy of Nurse Practitioners (AANP), Oncology Nursing Society (ONS), and Nightingale Honor Society. She was awarded the 2010 Arizona March of Dimes Nurse of the Year Award for Mentoring, and was recognized as the 2018 “Most Influential Nurse Mentor” in Tucson, Arizona. She has presented at numerous regional, national, and international lectures on oncology-related topics, including the pathobiology of cancer, differential diagnosis and risk adapted treatment, chemotherapy administration, symptom management, and clinical research.
She is an associate editor for The Journal of the Advanced Practitioner in Oncology, and is an editorial board member for JCO Clinical Cancer Informatics, The Oncology Nurse, Oncology: Nurse Edition, and the ASCO People Living with Cancer website. She is a founding board member and treasurer for APSHO, and has published numerous articles in peer-reviewed journals including the New England Journal of Medicine, Cancer Nursing, Clinical Leukemia, Blood, Leukemia Research, The Journal of the Advanced Practitioner in Oncology, and The Clinical Journal of Oncology Nursing.
Barbara Rogers, CRNP, MN, AOCN, ANP-BC, is a nurse practitioner at Fox Chase Cancer Center in Philadelphia, Pennsylvania, and a retired lieutenant colonel in the U.S. Army Reserve. She has 40 years of oncology experience with the majority of that time focused on the care of patients with hematologic malignancies.
Barbara has authored many peer-reviewed journal articles and book chapters, as well as given multiple presentations related to the care of patients with hematologic malignancies and symptom management of various treatments for malignancy.
She has held leadership positions in multiple organizations including serving on the ONS Board of Directors, chair of the ONS Nominating Committee, and chair of the Advanced Practice Test Development Committee of the Oncology Nursing Certification Corporation. Barbara is currently a member of the Education Committee of the Advanced Practitioner Society for Hematology and Oncology (APSHO).
Meredith Barnhart, LCSW-R, is the director of the Information Resource Center at The Leukemia & Lymphoma Society. In her role, she oversees 12 information specialists and one operations support coordinator who field inquiries from blood cancer patients and their loved ones. Meredith and her team provide comprehensive, personalized, and up-to-date information on blood cancers, treatment options including clinical trials, and support and financial resources.
Meredith earned her master’s from Columbia University and is currently pursuing a doctorate in social work from the Graduate School of Social Service at Fordham University. Her research focuses on the experiences and needs of families with multiple incidences of cancers.